You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)附屬與百奧賽圖簽署全人抗體藥物合作開發協議

格隆匯3月11日丨中國生物製藥(01177.HK)發佈公告,公司附屬公司南京正大天晴與百奧賽圖(北京)醫藥科技股份有限公司簽署了全人抗體藥物合作開發協議,共同合作開發針對雙方共同選定靶點的全人抗體藥物。據此,南京正大天晴領先的研發、製劑、原料三大平臺,將與百奧賽圖自主研發並擁有獨立知識產權的全人抗體RenMab平臺及獨具特色的全鏈條新藥研發體系相整合,共同合作開發針對雙方共同選定靶點的全人抗體藥物,發揮南京正大天晴成熟的臨牀開發及強大的生產銷售能力及百奧賽圖大規模全人抗體發現篩選的優勢,一起推進選定靶點的藥物研發,以期藥物早日上市惠及病患。

公告表示,集團具備雄厚的科研實力和強大的產業化能力。百奧賽圖RenMab平臺可快速產生親和力高、特異性和多樣性好的全人抗體,其正在開展的“千鼠萬抗”計劃能通過高通量篩選和循證體內藥效篩選獲得大量藥效好、安全性也好的候選抗體分子。集團期望通過此次合作,充分發揮雙方各自的平臺優勢,加速新藥研發和產業化,滿足未被滿足的臨牀需求,造福廣大病患。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account